Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-28
2011-06-28
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S275400
Reexamination Certificate
active
07968570
ABSTRACT:
The present invention is directed to compounds of formula I:wherein R1, R2, R3, R4, R5, R6, R7, R8, R9and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
REFERENCES:
patent: 3993617 (1976-11-01), Schwan
patent: 5681954 (1997-10-01), Yamamoto et al.
patent: 2004/0242572 (2004-12-01), Stenkamp et al.
patent: 620 654 (1963-01-01), None
patent: 1528923 (1978-10-01), None
patent: 0 548 934 (1993-06-01), None
patent: 0602814 (1994-06-01), None
patent: 1431267 (2004-06-01), None
patent: WO-92-17448 (1991-04-01), None
patent: WO-99-26927 (1999-06-01), None
patent: WO-02-10146 (2002-02-01), None
patent: WO-03-087044 (2003-10-01), None
patent: WO-2004-024702 (2004-03-01), None
patent: WO-2004-087048 (2004-10-01), None
patent: WO-2004-089897 (2004-10-01), None
patent: WO-2005-040157 (2005-05-01), None
patent: WO-2005-074643 (2005-08-01), None
patent: WO-2005-085214 (2005-09-01), None
patent: WO-2005-085216 (2005-09-01), None
Yamamoto et al. Org. Biomol. Chem. 2004, vol. 2, pp. 1287-1294.
Morissette et al. “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.” Advanced Drug Delivery Reviews 2004, 56, 275-300.
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry, pp. 217-218 (in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227).
Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
Yamamoto et al. Org. Biomol. Chem (2004); 2,1287-1294.
CA 139:133427 Synthetic Communications 33(7), 1087-1094, 2003.
Yamamoto Y. et al: vol. 2, No. 9, May 2004, pp. 1287-1294, XP002357868.
Moreau a et al: Tetrahedron, vol. 60, No. 29, Jul. 12, 2004, pp. 6169-6176 XP002357869.
Hatt H H et al: Journal of the Chemical Society, 1952, pp. 199-205 XP002357871.
Bohme H et al: Die Pharmazie, No. 25, 1970, pp. 283-289, XP002357872.
Mori M et al: Journal of Organic Chemistry, vol. 43, No. 9, Apr. 28, 1978, pp. 1864-1867, XP002357874.
Grigg R et al: Tetrahedron Letters, vol. 44, No. 37, Sep. 8, 2003, pp. 6979-6982, XP004447066.
Norman M H et al.: Journal of Medicinal Chemistry, vol. 39, No. 1, 1996, pp. 149-157, XP000982309.
Zhuang Z-P et al: Journal of Medicinal Chemistry, vol. 41, No. 2, Jan. 15, 1998, pp. 157-166, XP002357875.
Norman M H, et al: Journal of Medicinal Chemistry, vol. 36, No. 22, Oct. 29, 1993, pp. 3417-3423, XP002357876.
Ahn K H et al: Bioorganic & Medicinal Chemistry Letters, vol. 9, No. 10, May 17, 1999, pp. 1379-1384, XP004164896.
Sugimoto H et al: Journal of Medicinal Chemistry, vol. 35, No. 24, 1992, pp. 4542-4548, XP002319779.
Mayer P et al: Journal of Medicinal Chemistry, vol. 43, Sep. 19, 2000, pp. 3653-3664, XP001183987.
Breytenbach J C et al: Bioorganic & Medicinal Chemistry Letters, vol. 10, No. 15, Aug. 7, 2000, pp. 1629-1631, XP004213210.
Anderson P S et al: Journal of Organic Chemistry, vol. 44, No. 9, 1979, pp. 1519-1515, XP002981802.
Luzzio F A et al: Tetrahedron Letters, vol. 40, No. 11, Mar. 12, 1999, pp. 2087-2090, XP002357870.
CA 133:150436, Tetrahedron Letters, 41(20), 3891-3893, 2000.
CA 83:9678, Chemical & Pharmaceutical Bulletin, 23(1), 184-187, 1975.
CA 79:105030, Roczniki Chemii, 47(5), 937-942, 1973.
Clayton Joshua
Egle Ian
Empfield James
Isaac Methvin
Ma Fupeng
Anderson Rebecca L
Astrazeneca AB
Mitchell Kenneth F.
Otton Alicia L
LandOfFree
Isoindolone compounds and their use as metabotropic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isoindolone compounds and their use as metabotropic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoindolone compounds and their use as metabotropic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2640475